ReviewExpert review of anti-infective therapy2007
Novel approaches to bacterial infection therapy by interfering with bacteria-to-bacteria signaling.
Review in Expert review of anti-infective therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Stenotrophomonas maltophilia: Genotypic Characterization of Virulence Genes and The Effect of Ascorbic Acid on Biofilm Formation.Current microbiology · 2022Article
- Convergence of Biofilm Formation and Antibiotic Resistance inFrontiers in medicine · 2022Review
- Review of Systemic Antibiotic Treatments in Children with Rhinosinusitis.Journal of clinical medicine · 2019Review
- Modulation of antibiotic sensitivity and biofilm formation in Pseudomonas aeruginosa by interspecies signal analogues.Nature communications · 2019Article
- Screening of Natural Product Derivatives Identifies Two Structurally Related Flavonoids as Potent Quorum Sensing Inhibitors against Gram-Negative Bacteria.International journal of molecular sciences · 2018Article
- Anti-biofilm and Anti-Virulence Efficacy of Celastrol AgainstInternational journal of medical sciences · 2018Article
- Marine-derived quorum-sensing inhibitory activities enhance the antibacterial efficacy of tobramycin against Pseudomonas aeruginosa.Marine drugs · 2014Article
- Screening of Actinobacillus pleuropneumoniae LuxS inhibitors.Current microbiology · 2013Article
- Obacunone represses Salmonella pathogenicity islands 1 and 2 in an envZ-dependent fashion.Applied and environmental microbiology · 2012Article
- Critical role of LuxS in the virulence of Campylobacter jejuni in a guinea pig model of abortion.Infection and immunity · 2012Article
- Enhancing the utility of existing antibiotics by targeting bacterial behaviour?British journal of pharmacology · 2012Review
- Quorum sensing and bacterial social interactions in biofilms.Sensors (Basel, Switzerland) · 2012Review
- Identification of a key amino acid of LuxS involved in AI-2 production in Campylobacter jejuni.PloS one · 2011Article
- Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.Annual review of biochemistry · 2011Review
- Transition state analogs of 5'-methylthioadenosine nucleosidase disrupt quorum sensing.Nature chemical biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The growing challenge of antimicrobial resistance and the paucity of novel antibiotics underscore the importance of developing novel therapeutics. Bacterial cell-to-cell signaling constitutes a novel drug target. Quorum sensing (QS) is a cell-to-cell signaling mechanism that refers to the ability of bacteria to respond to chemical hormone-like molecules called autoinducers. QS is responsible for controlling a plethora of virulence genes in several bacterial pathogens. Antagonists to autoinducers will intercept bacterial intercellular communication, hindering their ability to act in a coordinated manner to express virulence traits. Moreover, since QS is not involved directly in essential processes, such as bacterial growth, one can reason that inhibition of QS will not yield a selective pressure for the development of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.